PTIX Stock Price, Protagenic Therapeutics, . Quote, Chart

Market Summary

USD1.38-0.19

Delayed

-12.10%

PTIX Stock Price

View Fullscreen

PTIX RSI Chart

PTIX Valuation

Market Cap

6.1M

Price/Earnings (Trailing)

-1.22

Price/Sales (Trailing)

0.19

EV/EBITDA

-1.25

Price/Free Cashflow

-1.65

PTIX Price/Sales (Trailing)

PTIX Profitability

EBT Margin

-12.96%

Return on Equity

-136.32%

Return on Assets

-115.66%

Free Cashflow Yield

-60.51%

PTIX Fundamentals

PTIX Revenue

Revenue (TTM)

38.6M

PTIX Earnings

Earnings (TTM)

-5.0M

Earnings Growth (Yr)

-178.73%

Earnings Growth (Qtr)

-20.02%

Breaking Down PTIX Revenue

Last 7 days

7.0%

Last 30 days

-24.2%

Last 90 days

55.1%

Trailing 12 Months

-24.2%

How does PTIX drawdown profile look like?

PTIX Financial Health

Current Ratio

6.41

PTIX Investor Care

Shares Dilution (1Y)

2.41%

Diluted EPS (TTM)

-1.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0
2011	0	0	38.6M	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Protagenic Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 12, 2023	arrow alexander k.	bought	6,480	0.81	8,000	chief financial officer
May 18, 2022	arrow alexander k.	bought	5,760	0.72	8,000	chief financial officer
May 17, 2022	arrow alexander k.	bought	16,330	0.71	23,000	chief financial officer
May 03, 2021	barrage khalil	acquired	532,500	1.47917	360,000	-
Apr 30, 2021	arrow alexander k.	bought	2,290	2.29	1,000	chief financial officer
Apr 29, 2021	arrow alexander k.	bought	2,290	2.29	1,000	chief financial officer

Which funds bought or sold PTIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	CWM, LLC	unchanged	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.65	-27,796	32,834	-%
Feb 15, 2024	GTS SECURITIES LLC	new	-	378	378	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	12,141	12,141	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-1.00	1.00	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-13,260	12,707	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-24,210	23,198	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	59.72	-1,462	8,936	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-1.00	1.00	-%
Feb 09, 2024	UBS Group AG	new	-	1.00	1.00	-%

Are Funds Buying or Selling PTIX?

Are funds buying PTIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PTIX

No. of Funds

Unveiling Protagenic Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	5.13%	240,000	SC 13G/A
Feb 14, 2023	armistice capital, llc	5.26%	960,000	SC 13G/A
Feb 15, 2022	armistice capital, llc	5.4%	960,000	SC 13G
Feb 04, 2022	hudson bay capital management lp	0%	0	SC 13G/A

Recent SEC filings of Protagenic Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	10-K/A	Annual Report
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	10-K	Annual Report
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 21, 2024	8-K	Current Report

Peers (Alternatives to Protagenic Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Protagenic Therapeutics, Inc. News

Latest updates

Protagenic Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)									(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2011Q3	2011Q2	2010Q3	2010Q2
Revenue	-	-	-	-	-	-	12,326,000	6,270,000	9,177,000	10,813,000
Costs and Expenses	-	-	-	-	-	-	17,344,000	11,293,000	12,845,000	15,301,000
Operating Expenses	-15.3%	1,212,226	1,431,712	1,143,742	739,294	655,778	-	-	-	-
S&GA Expenses	-100.0%	-	307,682	307,363	391,263	398,258	-	-	-	-
R&D Expenses	-10.0%	1,011,427	1,124,030	836,379	348,031	257,520	-	-	-	-
EBITDA Margin	-28.8%	-0.13	-0.10	-0.09	-0.07	-0.09	-	-	-	-
Interest Expenses	-59.8%	12,852	31,957	31,610	31,263	31,958	-	-	-	-
Earnings Before Taxes	-20.0%	-1,676,184	-1,396,626	-1,209,591	-718,096	-601,374	-	-	-	-
EBT Margin	-27.4%	-0.13	-0.10	-0.09	-0.08	-0.09	-	-	-	-
Net Income	-20.0%	-1,676,184	-1,396,626	-1,209,591	-718,096	-601,374	-	-	-	-
Net Income Margin	-27.4%	-0.13	-0.10	-0.09	-0.08	-0.09	-	-	-	-
Free Cashflow	-74.5%	-1,144,434	-655,766	-1,531,742	-371,834	-180,936	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-20.4%	4,323	5,433	6,919	7,666	8,037	8,254	9,015	9,798	11,060	11,657	12,062	6,471	879	1,002	1,188	786	842	287	350	465	697
Current Assets	-21.9%	4,200	5,377	6,918	7,665	8,036	8,254	9,015	9,798	11,060	11,657	12,062	196	879	1,002	1,188	786	842	287	349	464	696
Cash Equivalents	-100.0%	-	153	219	138	215	158	339	482	541	460	11,933	192	671	989	1,181	754	799	277	340	419	362
Net PPE	120.3%	123	56.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-	35*	117*	191*	296*	374*	463*	540*	611*
Liabilities	-48.8%	655	1,280	1,505	1,252	1,120	872	756	1,079	1,118	1,287	1,264	2,179	2,029	2,023	1,934	1,372	1,477	1,334	1,192	1,050	908
Current Liabilities	-48.8%	655	1,280	1,505	1,252	1,120	553	463	784	800	724	603	651	655	712	800	824	1,197	651	729	827	908
Shareholder's Equity	-11.7%	3,668	4,153	5,414	6,414	6,918	7,382	8,258	8,720	9,942	10,371	10,798	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-5.8%	-30,777	-29,101	-27,705	-26,495	-25,777	-25,176	-24,250	-23,583	-22,221	-21,331	-20,453	-18,905	-17,698	-17,175	-16,216	-15,648	-15,150	-14,400	-14,277	-13,998	-13,399
Additional Paid-In Capital	2.0%	34,559	33,872	33,705	33,538	33,371	33,171	32,957	32,701	32,412	31,873	31,420	17,093	16,720	16,326	15,643	15,237	14,687	14,209	14,070	13,809	13,358
Shares Outstanding	2.4%	4,435	4,331	4,331	4,331	4,321	4,321	4,320	4,308	4,302	4,130	3,122	2,630	2,590	-	-	-	-	-	-	-	-
Float	-	-	-	8,792	-	-	-	12,515	-	-	-	-	66,316	-	-	12,006	-	-	-	15,392	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-74.5%	-1,144	-655	-1,531	-371	-180	-535	-847	-430	-405	-1,075	-710	-607	-320	-517	-145	-364	-149	-61.76	-80.79	-196	-307
Share Based Compensation	0%	167	167	167	167	199	215	216	236	218	232	723	346	412	492	391	360	-53.01	139	261	451	261
Cashflow From Investing	285.6%	2,278	591	1,612	295	162	358	707	371	486	-	-	-	-	-	-	-	-	-	-	250	246
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	-	12,451	127	-	323	570	330	-	-	-	-	-

PTIX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
OPERATING AND ADMINISTRATIVE EXPENSES
Research and development	$ 3,319,867	$ 1,589,239
General and administrative	1,207,107	1,968,549
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES	4,526,974	3,557,788
LOSS FROM OPERATIONS	(4,526,974)	(3,557,788)
OTHER INCOME
Interest income	264,476	185,790
Interest expense	(107,682)	(137,456)
Realized loss on marketable securities	(630,317)	(46,051)
TOTAL OTHER INCOME	(473,523)	2,283
LOSS BEFORE TAX	(5,000,497)	(3,555,505)
INCOME TAX EXPENSE
NET LOSS	(5,000,497)	(3,555,505)
Other Comprehensive Loss - net of tax
Net unrealized gain (loss) on marketable securities	16,848	(421,738)
Reclassification of realized losses on debt securities	489,120
Foreign exchange translation income (loss)	57,393	(6,820)
TOTAL COMPREHENSIVE LOSS	$ (4,437,136)	$ (3,984,063)
Net loss per common share - Basic	$ (1.15)	$ (0.82)
Net loss per common share - Diluted	$ (1.15)	$ (0.82)
Weighted average common shares - Basic	4,344,580	4,317,875
Weighted average common shares - Diluted	4,344,580	4,317,875

PTIX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 1,287,893	$ 215,189
Marketable securities	2,768,119	7,763,517
Prepaid expenses	144,025	56,939
TOTAL CURRENT ASSETS	4,200,037	8,035,645
Equipment - net	123,332	1,775
TOTAL ASSETS	4,323,369	8,037,420
CURRENT LIABILITIES
TOTAL CURRENT LIABILITIES	655,252	1,119,862
TOTAL LIABILITIES	655,252	1,119,862
STOCKHOLDERS’ EQUITY
Preferred stock value
Common stock, $.0001 par value, 100,000,000 shares authorized, 4,435,132 and 4,321,315 shares issued and outstanding at December 31, 2023, and December 31, 2022	444	434
Additional paid-in-capital	34,559,091	33,371,406
Accumulated deficit	(30,777,872)	(25,777,375)
Accumulated other comprehensive loss	(113,546)	(676,907)
TOTAL STOCKHOLDERS’ EQUITY	3,668,117	6,917,558
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	4,323,369	8,037,420
Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock value
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock value
Nonrelated Party [Member]
CURRENT LIABILITIES
Accounts payable and accrued expenses	439,757	669,704
PIK convertible notes payable, net of debt discount		150,591
Related Party [Member]
CURRENT LIABILITIES
Accounts payable and accrued expenses	215,495	105,928
PIK convertible notes payable, net of debt discount		$ 193,639

About Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

0

WEBSITE	protagenic.com
INDUSTRY	Biotechnology

Protagenic Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Protagenic Therapeutics, Inc.? What does PTIX stand for in stocks?

PTIX is the stock ticker symbol of Protagenic Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protagenic Therapeutics, Inc. (PTIX)?

As of Fri Apr 26 2024, market cap of Protagenic Therapeutics, Inc. is 6.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTIX stock?

You can check PTIX's fair value in chart for subscribers.

What is the fair value of PTIX stock?

You can check PTIX's fair value in chart for subscribers. The fair value of Protagenic Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Protagenic Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Protagenic Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether PTIX is over valued or under valued. Whether Protagenic Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Protagenic Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTIX.

What is Protagenic Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, PTIX's PE ratio (Price to Earnings) is -1.22 and Price to Sales (PS) ratio is 0.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Protagenic Therapeutics, Inc.'s stock?

In the past 10 years, Protagenic Therapeutics, Inc. has provided 0.656 (multiply by 100 for percentage) rate of return.